We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

M:NYSEMacy's Inc Analysis

Data as of 2026-04-16 - not real-time

$19.15

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Macy's (M) is trading at $19.15, just shy of the near‑term resistance of $19.58 and comfortably above the 20‑day SMA of $18.33, indicating limited upside in the immediate window. The MACD histogram is positive and the signal line turned bullish, while the RSI sits at a neutral 56, suggesting no imminent overbought pressure. Fundamental metrics show a low trailing P/E of 8.25 and a price‑to‑book of 1.04, positioning the stock in the value space, and the dividend yield of 4% with a modest 31% payout ratio underscores decent cash return potential. However, revenue slipped 1.1% year‑over‑year, operating margins remain thin at 7.5%, and the balance sheet is leveraged with a debt‑to‑equity of 114%, flagging financial risk. Volatility is elevated at 35% over the past 30 days and beta around 1.33 points to higher systematic risk, while volume trends are weakening, hinting at waning short‑term buying interest. Analyst consensus remains neutral with a median price target of $20, implying only a modest 1.3% upside, and a DCF‑derived fair value of $5.9 starkly contrasts the current price, raising questions about valuation methodology. Overall, the stock presents a mixed picture: attractive valuation and dividend income against a backdrop of earnings pressure, high leverage, and sector cyclicality.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near resistance with decreasing volume
  • Bullish MACD but neutral RSI
  • Elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Recent earnings beat and solid dividend yield
  • Low valuation multiples relative to peers
  • High leverage and modest revenue decline

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Attractive P/E and P/B for a value play
  • Sustainable dividend with ample coverage
  • Potential upside if leverage is reduced and sales stabilize

Key Metrics & Analysis

Financial Health

Revenue Growth-1.10%
Profit Margin2.84%
P/E Ratio8.3
ROE13.64%
ROA3.36%
Debt/Equity114.55
P/B Ratio1.0
Op. Cash Flow$1.4B
Free Cash Flow$433.5M

Technical Analysis

TrendNeutral
RSI56.1
Support$16.69
Resistance$19.58
MA 20$18.33
MA 50$19.38
MA 200$18.24
MACDBullish
VolumeDecreasing
Fear & Greed Index88.98

Valuation

Fair Value$5.92
Target Price$19.40
Upside/Downside1.31%
GradeFair
TypeValue
Dividend Yield4.00%

Risk Assessment

Beta1.33
Volatility35.83%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.